Zoonotic cutaneous leishmaniasis (ZCL) is polymorphic disease with various clinical manifestations (
1,
2). Leishmaniasis, a group of parasitic infections, has a worldwide distribution (
3); the world health organization estimates a prevalence of approximately 12 million cases, with an annual mortality rate of 60,000 and an at-risk population of approximately 350 million (
4). Approximately 90% of CL cases occur in just seven countries, including Iran (
5). Several molecular targets for diagnostic PCR testing have been evaluated in
Leishmania, including minicircle kinetoplast DNA (kDNA) (
5,
6), the mini-exon (spliced leader RNA) gene (
7), gp63 polymerase chain reaction analysis of restriction fragment length polymorphism (PCR-RFLP) (
8), and the internal transcribed spacer (ITS) (
1,
3,
9,
10). PCR is a new alternative to existing diagnostic procedures, such as direct smear of parasites from clinical specimens or by cultivation, with microscopic examination.